Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04752722 · ClinicalTrials.gov registry record · Phase 1
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
A Phase 1 study of Non-muscle Invasive Bladder Cancer With Carcinoma in Situ and Superficial Bladder Cancer, sponsored by enGene.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT04752722: Recruiting Phase 1 study of Non-muscle Invasive Bladder Cancer With Carcinoma in Situ and Superficial Bladder Cancer, sponsored by enGene.
NCT04752722 is a Phase 1 study of Non-muscle Invasive Bladder Cancer With Carcinoma in Situ and Superficial Bladder Cancer that is actively recruiting participants, run by enGene. The registered enrollment target is 350 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (483% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04752722, a Phase 1 study of Non-muscle Invasive Bladder Cancer With Carcinoma in Situ and Superficial Bladder Cancer, is actively recruiting participants, sponsored by enGene.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or inadequately treated.
Primary Outcome
The type, incidence, relatedness and severity of treatment emergent adverse events of EG-70 as assessed by NCI-CTCAE V5.0 will be monitored.
Conditions Studied
Interventions
- DRUG EG-70 (phase 1)
- DRUG EG-70 (phase 2)
Study Locations (20)
California
- University of California - Irvine Medical Center - Irvine
- UC San Diego Moores Cancer Center - La Jolla
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Tower Urology - Los Angeles
- Genesis Research - San Diego
Arizona
- Mayo Clinic - Scottsdale
- Urological Associates of South Arizona - Tucson
Florida
- University of Florida - Jacksonville
- Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics - Miami
Maryland
- John Hopkins Hospital - Baltimore
- Chesapeake Urology Research Associates - Hanover
Alabama
- The University of Alabama at Birmingham Clinical Research Unit (CRU) - Birmingham
Arkansas
- Arkansas Urology - Little Rock
Colorado
- Colorado Clinical Research - Lakewood
District of Columbia
- The George Washington Medical Faculty Associates - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2021-04-22 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 1 |
What NCT04752722 shows while recruiting
NCT04752722 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (483% higher).
The record links to 2 conditions, with Non-muscle Invasive Bladder Cancer With Carcinoma in Situ appearing as the primary indexed condition, and to 2 interventions - of which EG-70 (phase 1) is the first listed.
NCT04752722 names 20 study sites across 13 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT04752722 about?
NCT04752722 is a clinical study titled "LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve". This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Pha...
What is the current status of trial NCT04752722?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 350 participants. The study started on 2021-04-22. Estimated completion is 2028-11-30.
What conditions does trial NCT04752722 study?
This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Superficial Bladder Cancer.
What interventions are being tested in trial NCT04752722?
The interventions under investigation include: EG-70 (phase 1) (DRUG), EG-70 (phase 2) (DRUG).
Who is sponsoring clinical trial NCT04752722?
This trial is sponsored by enGene, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04752722 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04752722's enrollment target sits among peer trials
350 97th of 2000 higher than 1,902 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI